ArticleAmerican journal of translational research2025
Predictive value of baseline serum sST2 and BNP levels for treatment efficacy in patients with heart failure.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the association between baseline serum soluble stimulator gene 2 (sST2) level, B-type natriuretic peptide (BNP) level and treatment outcomes in Heart failure (HF) patients, and to assess their predictive value.
methodsA retrospective case-control study was conducted on 162 HF patients treated at Longgang People's Hospital from August 2021 to July 2023. Patients were categorized into effective (n=138) and ineffective (n=24) groups based on New York Heart Association (NYHA) functional classification post-treatment. Serum sST2 and BNP levels were measured using enzyme-linked immunosorbent assay, and cardiac function parameters, including left ventricular ejection fraction (LVEF) were assessed via echocardiography.
resultsThe overall treatment effectiveness rate was 85.19%. The serum soluble ST2 and BNP levels in the ineffective group were significantly higher compared to the effective group (P<0.05). Additionally, LVEF was significantly lower, while the left ventricular end-systolic dimension (LVESD) was significantly greater in the ineffective group than in the effective group. Both serum sST2 and BNP were identified as independent risk factors for ineffective treatment. A combined predictive model incorporating soluble ST2 and BNP achieved an AUC of 0.929, demonstrating excellent predictive performance.
conclusionBaseline serum sST2 and BNP levels are independent predictors of treatment response in HF patients. Their combined application enhances predictive performance and may assist clinicians in tailoring treatment strategies to improve patient survival quality and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.